OR WAIT null SECS
William Lumry, MD: Founder of the Allergy & Asthma Specialists of Dallas
November 15, 2026
Video
Lumry discusses routine quality-of-life assessment, the pediatric HAE prophylaxis pipeline, and open questions after real-world lanadelumab data.
November 14, 2026
Caregiver-rated QoL rose from 1.9 to 4.5 on a 5-point scale with lanadelumab prophylaxis in a pediatric HAE registry analysis, William Lumry, MD, said.
William R. Lumry, MD, reports a 95% drop in attack frequency after lanadelumab initiation in a real-world chart review of 13 pediatric patients with HAE.
October 08, 2025
Donidalorsen demonstrates strong efficacy in patients switching from other HAE prophylactic treatments. Lumry discusses pivotal data after FDA approval.